Table 1.
Baseline Characteristics of Participants
| Parameters | Eplerenone, n = 21 | Placebo, n = 21 | P Value |
|---|---|---|---|
| Clinical characteristics | |||
| LVEF, % | 61.1 ± 6.8 | 61.8 ± 7.0 | 0.75 |
| BMI, kg/m2 | 27.6 ± 3.2 | 26.6 ± 3.7 | 0.35 |
| Office SBP, mm Hg | 129.9 ± 9.6 | 133.0 ± 13.5 | 0.39 |
| Office DBP, mm Hg | 79.5 ± 8.5 | 79.0 ± 8.7 | 0.83 |
| Heart rate, bpm | 58.8 ± 9.3 | 59.9 ± 8.2 | 0.69 |
| Comorbidities | |||
| History of smoking | 11 (52) | 11 (55) | 0.87 |
| Dyslipidemia | 19 (90) | 18 (86) | 0.63 |
| HTN | 14 (67) | 13 (62) | 0.75 |
| DM | 0 (0) | 0 (0) | — |
| History of MI | 16 (76) | 15 (71) | 0.40 |
| Family history for CAD | 15 (79) | 12 (67) | 0.40 |
| CV risk factors | 3.5 ± 1.0 | 3.0 ± 1.0 | 0.11 |
| Concomitant drug therapy | |||
| ASA | 19 (90) | 21 (100) | 0.09 |
| Clopidogrel | 10 (48) | 4 (19) | 0.05 |
| ACEI and/or ARB | 12 (57) | 14 (67) | 0.53 |
| β‐Blocker | 14 (67) | 15 (71) | 0.74 |
| CCB | 5 (24) | 4 (19) | 0.71 |
| Diuretic | 3 (14) | 5 (24) | 0.43 |
| Statin | 19 (90) | 21 (100) | 0.09 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CV, cardiovascular; DBP, diastolic blood pressure; DM, diabetes mellitus; HR, heart rate; HTN, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; SBP, systolic blood pressure; SD, standard deviation.
Values are presented as n (%) or mean ± SD.